Macrophage inhibitory cytokine-1 (MIC-1/GDF15) slows cancer development but increases metastases in TRAMP prostate cancer prone mice

PLoS ONE

Volumn 7, Issue 8, 2012, Pages

  Husaini, Yasmin ^a   Qiu, Min Ru ^b   Lockwood, Glen P ^a   Luo, Xu Wei ^a   Shang, Ping ^a   Kuffner, Tamara ^a   Tsai, Vicky Wang Wei ^a   Jiang, Lele ^a   Russell, Pamela J ^c   Brown, David A ^a   Breit, Samuel N ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b ST VINCENT S HOSPITAL   (Australia)

^c QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH DIFFERENTIATION FACTOR 15;

ADVANCED CANCER; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER GRADING; CANCER INHIBITION; CANCER RISK; CANCER SURVIVAL; CARCINOGENESIS; CONTROLLED STUDY; DISTANT METASTASIS; HISTOPATHOLOGY; MALE; MALIGNANT TRANSFORMATION; METASTASIS; MOUSE; NONHUMAN; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; SURVIVAL RATE; SURVIVAL TIME; TUMOR GROWTH; TUMOR VOLUME; UROGENITAL TRACT TUMOR;

ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE SUSCEPTIBILITY; FEMALE; GROWTH DIFFERENTIATION FACTOR 15; MALE; MICE; MICE, TRANSGENIC; NEOPLASM GRADING; NEOPLASM METASTASIS; PROSTATIC NEOPLASMS; RECEPTORS, TUMOR NECROSIS FACTOR, MEMBER 25; SURVIVAL ANALYSIS;

EID: 84865421888     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0043833     Document Type: Article

References (57)

1. American C (2011) Cancer Facts & Figures. Atlanta: American Cancer Society.
2. Bootcov MR, Bauskin AR, Valenzuela SM, Moore AG, Bansal M, et al. (1997) MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-beta superfamily. Proc Natl Acad Sci U S A 94: 11514-11519.
3. Bauskin AR, Brown DA, Kuffner T, Johnen H, Luo XW, et al. (2006) Role of macrophage inhibitory cytokine-1 in tumorigenesis and diagnosis of cancer. Cancer Res 66: 4983-4986.
4. Breit SN, Johnen H, Cook AD, Tsai VW, Mohammad MG, et al. (2011) The TGF-beta superfamily cytokine, MIC-1/GDF15: a pleotrophic cytokine with roles in inflammation, cancer and metabolism. Growth Factors 29: 187-195.
5. Welsh JB, Sapinoso LM, Kern SG, Brown DA, Liu T, et al. (2003) Large-scale delineation of secreted protein biomarkers overexpressed in cancer tissue and serum. Proc Natl Acad Sci U S A 100: 3410-3415.
6. Joiner MC, Thomas RA, Grever WE, Smolinski JM, Divine GW, et al. (2011) Developing point of care and high-throughput biological assays for determining absorbed radiation dose. Radiother Oncol 101: 233-236.
7. Boyer J, Allen WL, McLean EG, Wilson PM, McCulla A, et al. (2006) Pharmacogenomic identification of novel determinants of response to chemotherapy in colon cancer. Cancer Res 66: 2765-2777.
8. Modlich O, Prisack HB, Munnes M, Audretsch W, Bojar H, (2004) Immediate gene expression changes after the first course of neoadjuvant chemotherapy in patients with primary breast cancer disease. Clin Cancer Res 10: 6418-6431.
9. Huang CY, Beer TM, Higano CS, True LD, Vessella R, et al. (2007) Molecular alterations in prostate carcinomas that associate with in vivo exposure to chemotherapy: identification of a cytoprotective mechanism involving growth differentiation factor 15. Clin Cancer Res 13: 5825-5833.
10. Rasiah KK, Kench JG, Gardiner-Garden M, Biankin AV, Golovsky D, et al. (2006) Aberrant neuropeptide Y and macrophage inhibitory cytokine-1 expression are early events in prostate cancer development and are associated with poor prognosis. Cancer Epidemiol Biomarkers Prev 15: 711-716.
11. Noorali S, Kurita T, Woolcock B, de Algara TR, Lo M, et al. (2007) Dynamics of expression of growth differentiation factor 15 in normal and PIN development in the mouse. Differentiation 75: 325-336.
12. Bauskin AR, Jiang L, Luo XW, Wu L, Brown DA, et al. (2010) The TGF-beta superfamily cytokine MIC-1/GDF15: secretory mechanisms facilitate creation of latent stromal stores. J Interferon Cytokine Res 30: 389-397.
13. Brown DA, Ward RL, Buckhaults P, Liu T, Romans KE, et al. (2003) MIC-1 serum level and genotype: associations with progress and prognosis of colorectal carcinoma. Clin Cancer Res 9: 2642-2650.
14. Brown DA, Lindmark F, Stattin P, Balter K, Adami HO, et al. (2009) Macrophage inhibitory cytokine 1: a new prognostic marker in prostate cancer. Clin Cancer Res 15: 6658-6664.
15. Brown DA, Stephan C, Ward RL, Law M, Hunter M, et al. (2006) Measurement of serum levels of macrophage inhibitory cytokine 1 combined with prostate-specific antigen improves prostate cancer diagnosis. Clin Cancer Res 12: 89-96.
16. Lee DH, Yang Y, Lee SJ, Kim KY, Koo TH, et al. (2003) Macrophage inhibitory cytokine-1 induces the invasiveness of gastric cancer cells by up-regulating the urokinase-type plasminogen activator system. Cancer Res 63: 4648-4655.
17. Nakamura T, Scorilas A, Stephan C, Yousef GM, Kristiansen G, et al. (2003) Quantitative analysis of macrophage inhibitory cytokine-1 (MIC-1) gene expression in human prostatic tissues. Br J Cancer 88: 1101-1104.
18. Cheung PK, Woolcock B, Adomat H, Sutcliffe M, Bainbridge TC, et al. (2004) Protein profiling of microdissected prostate tissue links growth differentiation factor 15 to prostate carcinogenesis. Cancer Res 64: 5929-5933.
19. Koopmann J, Buckhaults P, Brown DA, Zahurak ML, Sato N, et al. (2004) Serum macrophage inhibitory cytokine 1 as a marker of pancreatic and other periampullary cancers. Clin Cancer Res 10: 2386-2392.
20. Chen SJ, Karan D, Johansson SL, Lin FF, Zeckser J, et al. (2007) Prostate-derived factor as a paracrine and autocrine factor for the proliferation of androgen receptor-positive human prostate cancer cells. Prostate 67: 557-571.
21. Selander KS, Brown DA, Sequeiros GB, Hunter M, Desmond R, et al. (2007) Serum macrophage inhibitory cytokine-1 concentrations correlate with the presence of prostate cancer bone metastases. Cancer Epidemiol Biomarkers Prev 16: 532-537.
22. Baek KE, Yoon SR, Kim JT, Kim KS, Kang SH, et al. (2009) Upregulation and secretion of macrophage inhibitory cytokine-1 (MIC-1) in gastric cancers. Clin Chim Acta 401: 128-133.
23. Shnaper S, Desbaillets I, Brown DA, Murat A, Migliavacca E, et al. (2009) Elevated levels of MIC-1/GDF15 in the cerebrospinal fluid of patients are associated with glioblastoma and worse outcome. Int J Cancer 125: 2624-2630.
24. Zhao L, Lee BY, Brown DA, Molloy MP, Marx GM, et al. (2009) Identification of candidate biomarkers of therapeutic response to docetaxel by proteomic profiling. Cancer Res 69: 7696-7703.
25. Wallin U, Glimelius B, Jirstrom K, Darmanis S, Nong RY, et al. (2011) Growth differentiation factor 15: a prognostic marker for recurrence in colorectal cancer. Br J Cancer 104: 1619-1627.
26. Staff AC, Bock AJ, Becker C, Kempf T, Wollert KC, et al. (2010) Growth differentiation factor-15 as a prognostic biomarker in ovarian cancer. Gynecol Oncol 118: 237-243.
27. Staff AC, Trovik J, Eriksson AG, Wik E, Wollert KC, et al. (2011) Elevated plasma growth differentiation factor-15 correlates with lymph node metastases and poor survival in endometrial cancer. Clin Cancer Res 17: 4825-4833.
28. Boyle GM, Pedley J, Martyn AC, Banducci KJ, Strutton GM, et al. (2009) Macrophage inhibitory cytokine-1 is overexpressed in malignant melanoma and is associated with tumorigenicity. J Invest Dermatol 129: 383-391.
29. Suesskind D, Schatz A, Schnichels S, Coupland SE, Lake SL, et al. (2011) GDF-15: a novel serum marker for metastases in uveal melanoma patients. Graefes Arch Clin Exp Ophthalmol.
30. Koopmann J, Rosenzweig CN, Zhang Z, Canto MI, Brown DA, et al. (2006) Serum markers in patients with resectable pancreatic adenocarcinoma: macrophage inhibitory cytokine 1 versus CA19-9. Clin Cancer Res 12: 442-446.
31. Weber F, Shen L, Aldred MA, Morrison CD, Frilling A, et al. (2005) Genetic classification of benign and malignant thyroid follicular neoplasia based on a three-gene combination. J Clin Endocrinol Metab 90: 2512-2521.
32. Fluge O, Bruland O, Akslen LA, Lillehaug JR, Varhaug JE, (2006) Gene expression in poorly differentiated papillary thyroid carcinomas. Thyroid 16: 161-175.
33. Johnen H, Lin S, Kuffner T, Brown DA, Tsai VW, et al. (2007) Tumor-induced anorexia and weight loss are mediated by the TGF-beta superfamily cytokine MIC-1. Nat Med 13: 1333-1340.
34. Bauskin AR, Brown DA, Junankar S, Rasiah KK, Eggleton S, et al. (2005) The propeptide mediates formation of stromal stores of PROMIC-1: role in determining prostate cancer outcome. Cancer Res 65: 2330-2336.
35. Baek SJ, Kim KS, Nixon JB, Wilson LC, Eling TE, (2001) Cyclooxygenase inhibitors regulate the expression of a TGF-beta superfamily member that has proapoptotic and antitumorigenic activities. Mol Pharmacol 59: 901-908.
36. Liu T, Bauskin AR, Zaunders J, Brown DA, Pankhurst S, et al. (2003) Macrophage inhibitory cytokine 1 reduces cell adhesion and induces apoptosis in prostate cancer cells. Cancer Res 63: 5034-5040.
37. Kim JS, Baek SJ, Sali T, Eling TE, (2005) The conventional nonsteroidal anti-inflammatory drug sulindac sulfide arrests ovarian cancer cell growth via the expression of NAG-1/MIC-1/GDF-15. Mol Cancer Ther 4: 487-493.
38. Pang RP, Zhou JG, Zeng ZR, Li XY, Chen W, et al. (2007) Celecoxib induces apoptosis in COX-2 deficient human gastric cancer cells through Akt/GSK3beta/NAG-1 pathway. Cancer Lett 251: 268-277.
39. Lee SH, Kim JS, Yamaguchi K, Eling TE, Baek SJ, (2005) Indole-3-carbinol and 3,3'-diindolylmethane induce expression of NAG-1 in a p53-independent manner. Biochem Biophys Res Commun 328: 63-69.
40. Kim KK, Lee JJ, Yang Y, You KH, Lee JH, (2008) Macrophage inhibitory cytokine-1 activates AKT and ERK-1/2 via the transactivation of ErbB2 in human breast and gastric cancer cells. Carcinogenesis 29: 704-712.
41. Zhang L, Yang X, Pan HY, Zhou XJ, Li J, et al. (2009) Expression of growth differentiation factor 15 is positively correlated with histopathological malignant grade and in vitro cell proliferation in oral squamous cell carcinoma. Oral Oncol 45: 627-632.
42. Senapati S, Rachagani S, Chaudhary K, Johansson SL, Singh RK, et al. (2010) Overexpression of macrophage inhibitory cytokine-1 induces metastasis of human prostate cancer cells through the FAK-RhoA signaling pathway. Oncogene 29: 1293-1302.
43. Albertoni M, Shaw PH, Nozaki M, Godard S, Tenan M, et al. (2002) Anoxia induces macrophage inhibitory cytokine-1 (MIC-1) in glioblastoma cells independently of p53 and HIF-1. Oncogene 21: 4212-4219.
44. Greenberg NM, DeMayo F, Finegold MJ, Medina D, Tilley WD, et al. (1995) Prostate cancer in a transgenic mouse. Proc Natl Acad Sci U S A 92: 3439-3443.
45. Gingrich JR, Barrios RJ, Morton RA, Boyce BF, DeMayo FJ, et al. (1996) Metastatic prostate cancer in a transgenic mouse. Cancer Res 56: 4096-4102.
46. Hurwitz AA, Foster BA, Allison JP, Greenberg NM, Kwon ED (2001) The TRAMP mouse as a model for prostate cancer. Curr Protoc Immunol Chapter 20: Unit 20 25.
47. Gingrich JR, Barrios RJ, Foster BA, Greenberg NM, (1999) Pathologic progression of autochthonous prostate cancer in the TRAMP model. Prostate Cancer Prostatic Dis 2: 70-75.
48. Foster BA, Gingrich JR, Kwon ED, Madias C, Greenberg NM, (1997) Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model. Cancer Res 57: 3325-3330.
49. Jeet V, Ow K, Doherty E, Curley B, Russell PJ, et al. (2008) Broadening of transgenic adenocarcinoma of the mouse prostate (TRAMP) model to represent late stage androgen depletion independent cancer. Prostate 68: 548-562.
50. Yang H, Filipovic Z, Brown D, Breit SN, Vassilev LT, (2003) Macrophage inhibitory cytokine-1: a novel biomarker for p53 pathway activation. Mol Cancer Ther 2: 1023-1029.
51. Zimmers TA, Jin X, Hsiao EC, Perez EA, Pierce RH, et al. (2006) Growth differentiation factor-15: induction in liver injury through p53 and tumor necrosis factor-independent mechanisms. J Surg Res 130: 45-51.
52. Kelly JA, Lucia MS, Lambert JR, (2009) p53 controls prostate-derived factor/macrophage inhibitory cytokine/NSAID-activated gene expression in response to cell density, DNA damage and hypoxia through diverse mechanisms. Cancer Lett 277: 38-47.
53. Brown DA, Moore J, Johnen H, Smeets TJ, Bauskin AR, et al. (2007) Serum macrophage inhibitory cytokine 1 in rheumatoid arthritis: a potential marker of erosive joint destruction. Arthritis Rheum 56: 753-764.
54. Baek SJ, Okazaki R, Lee SH, Martinez J, Kim JS, et al. (2006) Nonsteroidal anti-inflammatory drug-activated gene-1 over expression in transgenic mice suppresses intestinal neoplasia. Gastroenterology 131: 1553-1560.
55. Zimmers TA, Gutierrez JC, Koniaris LG, (2010) Loss of GDF-15 abolishes sulindac chemoprevention in the ApcMin/+ mouse model of intestinal cancer. J Cancer Res Clin Oncol 136: 571-576.
56. Brown DA, Hance KW, Rogers CJ, Sansbury LB, Albert PS, et al. (2012) Serum Macrophage Inhibitory Cytokine-1 (MIC-1/GDF15): A Potential Screening Tool for the Prevention of Colon Cancer? Cancer Epidemiol Biomarkers Prev 21: 337-346.
57. Massague J, (2008) TGFbeta in Cancer. Cell 134: 215-230.